Oncolytics Biotech (NASDAQ:ONCY) Upgraded to “Moderate Buy” at Raymond James
Raymond James upgraded shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) to a moderate buy rating in a research report released on Thursday morning,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) […]
More Stories
DOJ Sues California After Flagging 20,000 ‘Likely Noncitizens’ Registered to Vote
By Jill McLaughlin The Department of Justice (DOJ) filed a lawsuit against California on Oct. 15 over its voter list...
Ukraine Resumes Strikes on Russian Refineries as Zelenskyy Says ‘We’re Done’ With Trump’s Energy Truce
By Guy Birchall Ukraine has resumed attacks on Russian refineries after Ukrainian President Volodymyr Zelenskyy said Kyiv was “done” complying...
Musk Says US Government Is Controlling Starshield Services Amid Reported Disruptions in Ukraine
By Ryan Morgan SpaceX CEO Elon Musk denied reports that the company curbed its military-oriented Starshield satellite internet service in...
2027 Social Security Payment Boost Announced: 4 Things to Know
By Jack Phillips Social Security officials on Wednesday announced the largest cost-of-living adjustment (COLA) for retired beneficiaries in four years,...
IEA to Accelerate Emergency Release of 100 Million Barrels of Oil
By Jack Phillips The International Energy Agency (IEA) has announced that its member nations will hasten the release of emergency...
US Producer Inflation Posts Sharpest Monthly Gain Since 2022
By Andrew Moran U.S. producer inflation posted its sharpest monthly increase since Russia’s invasion of Ukraine in March 2022, new...